Numeco, an affiliate of Medytox, said Thursday it has received approval from Ukraine’s Ministry of Health for its botulinum toxin product Newlux (marketed overseas as Medinox).
This marks Numeco’s third approval in Europe, following Georgia and Moldova.
The company said it plans to pursue a combined marketing strategy in Ukraine, linking Newlux with Medytox’s hyaluronic acid filler Neuramis.
Newlux 100-unit product (Courtesy of Medytox)
Neuramis has maintained strong brand recognition in Ukraine since 2017 and recently obtained MDR CE certification.
A Numeco official described the Ukrainian approval as a “key step for Eastern European expansion,” adding that the company aims to strengthen its global presence through partnerships and product synergies.
Lee Han-soo
댓글
0